Skip to main
CLYM

CLYM Stock Forecast & Price Target

CLYM Analyst Ratings

Based on 12 analyst ratings
Strong Buy
Strong Buy 58%
Buy 42%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Climb Bio is a clinical-stage biotechnology company with a solid financial foundation and a promising drug pipeline, including their lead drug Uplizna and new drug budoprutug. Despite industry risks, Climb Bio is expected to see positive outcomes in the next 18 months due to their strong financial position and potential in multiple therapeutic areas.

Bears say

Climb Bio is a clinical-stage biotechnology company with a focus on developing therapeutics for immune-mediated diseases. While they have received FDA Fast Track Designation for their lead candidate, Budoprutug, for the treatment of primary membranous nephropathy (pMN), there are currently no approved treatments for this indication in the US alone. The company also faces potential competition from off-label use of anti-CD20 monoclonal antibodies, and the potential for CD19 inhibition to provide deeper B-cell depletion may not be enough to outweigh the risk of unwanted side effects with this novel modality.

CLYM has been analyzed by 12 analysts, with a consensus rating of Strong Buy. 58% of analysts recommend a Strong Buy, 42% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Climb Bio Inc (CLYM) Forecast

Analysts have given CLYM a Strong Buy based on their latest research and market trends.

According to 12 analysts, CLYM has a Strong Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Climb Bio Inc (CLYM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.